Financial Performance - The company's revenue for Q3 2025 was CNY 434,039,140.82, a decrease of 17.58% compared to the same period last year[4]. - Net profit attributable to shareholders was CNY 95,386,910.53, down 44.96% year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 87,420,564.88, a decline of 47.30% compared to the previous year[4]. - Total operating revenue for the current period is CNY 1,297,151,783.88, a decrease of 11.5% compared to CNY 1,466,382,190.25 in the previous period[23]. - Net profit for the current period is CNY 325,043,838.11, down 36.6% from CNY 513,721,618.43 in the previous period[23]. - Basic and diluted earnings per share decreased to CNY 0.6250 from CNY 0.9877 in the previous period[24]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,795,843,533.73, a decrease of 4.75% from the end of the previous year[4]. - Total assets decreased to CNY 5,795,843,533.73 from CNY 6,084,668,329.15, reflecting a decline of 4.8%[22]. - Total liabilities decreased to CNY 208,507,495.73 from CNY 422,296,129.26, a reduction of 50.7%[22]. - Total equity attributable to shareholders of the parent company is CNY 5,587,336,038.00, down from CNY 5,662,372,199.89, a decrease of 1.3%[22]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY 243,189,087.54, down 48.52% year-on-year[10]. - Operating cash flow for the current period is ¥243,189,087.54, a decrease of 48.5% compared to ¥472,383,146.22 in the previous period[26]. - Cash inflow from sales of goods and services decreased to ¥1,487,441,497.12 from ¥1,654,515,536.61, a decline of 10.1%[25]. - Total cash outflow related to operating activities increased to ¥1,340,107,227.73 from ¥1,263,632,312.27, a rise of 6.1%[26]. - The ending cash and cash equivalents balance is ¥1,149,685,975.52, down from ¥2,994,356,402.08, a decrease of 61.5%[26]. - The net increase in cash and cash equivalents was CNY -689,054,276.40, a 113.40% increase in cash outflow compared to the previous year[10]. Shareholder Information - The total number of shares held by the top 10 unrestricted shareholders includes 23,400,000 shares held by Harbin Sanlian Pharmaceutical Co., Ltd.[13]. - The company has a total of 341,485,000 restricted shares at the end of the period, with 103,860,500 shares released during the current period[17]. - The company has not disclosed any relationships or concerted actions among the top shareholders[13]. - The company has a total of 500,000 shares held by executive shareholders that are subject to lock-up regulations during their tenure[15]. - The company plans to unlock 50% of the shares held by certain incentive plan participants upon the expiration of the lock-up period[17]. - The company has not reported any changes in the top 10 shareholders due to securities lending or borrowing activities[13]. Expenses and Investments - Total operating costs increased to CNY 961,799,189.17, up 18.6% from CNY 810,701,627.08 in the previous period[23]. - Research and development expenses increased to CNY 36,311,309.94, up from CNY 31,356,409.16, indicating a growth of 15.4%[23]. - Cash outflow for employee compensation increased to ¥98,635,741.41 from ¥75,815,548.79, an increase of 30.2%[26]. - Cash outflow for investment activities rose to ¥953,953,449.69, up from ¥422,418,056.13, representing an increase of 126.9%[26]. - Net cash flow from investment activities is negative at -¥328,253,531.28, an improvement from -¥392,326,122.99 in the previous period[26]. Government Support - The company received government subsidies amounting to CNY 44,358,185.28, a 725.17% increase compared to the previous year[10]. Other Notable Changes - The company reported a significant increase in prepayments, which rose by 233.77% to CNY 82,363,906.29, mainly due to increased promotional expenses[9]. - The company experienced a 28857.97% increase in contract liabilities, reaching CNY 33,082,707.15, attributed to increased advance payments received[9]. - The company has not undergone an audit for the third quarter financial report[28].
敷尔佳(301371) - 2025 Q3 - 季度财报